Xeris Biopharma Holdings, Inc. provided revenue guidance for the full year 2024. For the year, the company expects tightening 2024 total revenue guidance to $175 million to $200 million.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
2.425 USD | +7.54% | +24.74% | +1.91% |
May. 30 | Sector Update: Health Care Stocks Higher in Afternoon Trading | MT |
May. 30 | Xeris Biopharma Says Potential Levothyroxine Injection Preferred Over Oral Formulation; Shares Rise | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+1.91% | 334M | |
+41.92% | 739B | |
+32.52% | 598B | |
-5.65% | 353B | |
+16.97% | 318B | |
+4.33% | 285B | |
+16.34% | 240B | |
+9.66% | 210B | |
-5.24% | 206B | |
+7.36% | 164B |
- Stock Market
- Equities
- XERS Stock
- News Xeris Biopharma Holdings, Inc.
- Xeris Biopharma Holdings, Inc. Provides Revenue Guidance for the Full Year 2024